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Drug target identiﬁcation is a key step in the development of
effective therapeutic agents. In this issue, we present the current
status of some validated and potential targets in drug discovery for
developing therapeutic agents for the treatment of cancer, inﬂam-
mation, cardiovascular diseases, neurodegenerative diseases, HIV,
and inﬂuenza A virus. I am indebted to my colleagues for their
cooperation and efforts to ﬁnd time from their busy schedule to
contribute to this issue. Also I would like to thank, on behalf of all
the contributors, the journal for providing us an opportunity to
share our thoughts on these interesting topics and hope this issue
will beneﬁt research scientists in their pursues related to these
topics.
The ﬁrst article, from Binghe Wang and colleagues, describes
the recent development in making prodrugs of pharmaceutically
acceptable forms of therapeutic hydrogen sulﬁde. Recent years
have seen a signiﬁcantly increased level of interests in gaseous
signaling molecules, which include nitric oxide (NO), carbon
monoxide (CO), and hydrogen sulﬁde. These molecules are
produced endogenously and play key regulatory roles in mammals.
Naturally, they are also excellent targets for the development of
therapeutics. One key challenge in developing gaseous molecules
as therapeutics is in their safe and controlled delivery. Prodrug is a
very effective approach to address this challenge.
Cancer metastasis is the primary cause of morbidity and
mortality, and responsible for about 90% of cancer deaths.
Although cancer survival rate has been signiﬁcantly improved
over the years, the improvement is primarily due to early diagnosis
and cancer growth inhibition. Limited progress has been made in
the treatment of cancer metastasis. Xiangming Guan provides an
overview of the metastatic process with a focus on the four
essential steps (detachment, migration, invasion and adhesion),
related biochemical parameters, and targets for metastasis preven-
tion and inhibition.
Related to cancer treatment, hypoxia-inducible factor-1 (HIF-1)
has been recognized for two decades to play a signiﬁcant role in16/j.apsb.2016.08.002
esponsibility of Institute of Materia Medica, Chinese Accancer growth and metastasis. Its selective expression in solid
tumor has made it an attractive target for the development of
anticancer agents. Wei Li and Georgina N Masoud provide an
overview of the current status of HIF-1, its related regulatory
pathway, and targets for anticancer drug development.
Oxidative stress has been associated with a number of patho-
logical conditions such as inﬂammation, neurodegenerative dis-
eases, cardiovascular diseases, diabetes, cancer, and etc. The
antioxidant enzyme system protects cells against oxidative stress
through elevating a number of cytoprotective oxidative stress
response enzymes. Longqin Hu and colleagues provide a review
on a protein-protein interaction (PPI) (the Keap1–Nrf2 protein–
protein interaction) that affects the expression of these cytopro-
tective oxidative stress response enzymes, and inhibition of the
PPI to increase the expression of these enzymes. Screening
methods for developing the inhibitors of the PPI are also
presented.
Two reviews are devoted to viral infections. One is provided by
Wei Wang and colleagues with a focus on Inﬂuenza A. Inﬂuenza
A virus causes seasonal or pandemic ﬂu, which remains as one of
the major plagues worldwide with high morbidity and signiﬁcant
mortality. The increasing frequency of viral resistance to the
current clinically used anti-inﬂuenza virus drugs, particularly to
amantadine and oseltamivir, underlines an urgent need for novel
antiviral drugs against resistant inﬂuenza A virus. Wei Wang and
colleagues present a brief review of the molecular mechanism
behind the resistance and discuss recent progresses and potential
strategies in developing new small-molecule compounds to over-
come inﬂuenza A virus resistance. On the other hand, Feng Li and
colleagues provide an overview of pharmacological intervention of
human immunodeﬁciency virus (HIV) maturation and HIV drug
resistance. Increasing drug resistance and toxicities observed
among many of the current approved HIV drugs post a need for
developing anti-HIV agents with a safe proﬁle and novel mechan-
ism of action. Inhibition of HIV maturation has been identiﬁed asademy of Medical Sciences and Chinese Pharmaceutical Association.
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maturation is the ﬁnal step of virus replication. In this review, the
process of HIV maturation and current status of HIV maturation
inhibitors are presented.
Finally, Li Niu provides a review on 2,3-benzodiazepine com-
pounds. These compounds are designed to be noncompetitive
antagonists for a better control of the activity of AMPA receptors.
AMPA receptors are a group of ligand-gated ion channel receptors
exclusively expressed in the central nervous system. Excessive
activities of these receptors and/or elevated receptor expression play
signiﬁcant roles in a number of neurodegenerative disorders and
diseases such as epilepsy, amyotrophic lateral sclerosis and stroke.
Potent and selective 2,3-benzodiazepine AMPA receptor inhibitors,
especially single subunit-selective inhibitors, may help improve
efﬁcacy and reduce side effects for these compounds when they are
used as potential drugs for the treatment of these neurological
diseases. Currently these compounds are a class of the most
promising drug candidates targeting AMPA receptors.
I hope this issue provides our readers a comprehensive background
and current views on the presented topics, and helps researchers in
their search for effective therapeutic agents, as well as stimulates
further research interests to move the ﬁelds forward.Articles
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in Medicinal Chemistry in 1991 fromUniversity of Kansas, USA. Dr. Guan did one year postdoctoral
training in the Department of Pharmaceutics, University of Kansas
and continued his postdoctoral training in drug metabolism in the
Department of Medicinal Chemistry, University of Washington
before he joined the Department of Pharmaceutical Sciences at
South Dakota State University in 1995 to start his independent
research. He was tenured in 2000, promoted to Professor in 2005
and currently serves as the Assistant Dean for Research in the
College of Pharmacy, South Dakota State University.
Dr. Guan's research is focused on developing agents/approaches of
biomedical/pharmaceutical interests. His research group is character-
ized by touching various research disciplines that include drug design,
organic synthesis, bioanalytical chemistry, enzymology, molecular
biology, and drug metabolism. Currently, he is working on two major
projects. One is to develop thiol speciﬁc ﬂuorogenic reagents for thiol
imaging and quantiﬁcation in live cells through ﬂuorescence micro-
scopy. Due to the signiﬁcant roles thiols play in various physiolo-
gical/pathological functions, numerous analytical methods have been
developed for thiol assays. However, none of those can be used for
thiol imaging and quantiﬁcation in live cells through ﬂuorescence
microscopy. Monitoring an analyte in live cells through ﬂuorescence
microscopy provides the advantage of allowing visualization of the
analyte in its intact and native physiological environment and
revealing the information that cannot be revealed by most other
conventional analytical methods. Dr. Guan's group has identiﬁed a
thiol speciﬁc thiol-sulﬁde exchange reaction. Based on this reaction, anumber of thiol speciﬁc ﬂuorogenic reagents have been developed.
One of the reagents was developed as the ﬁrst reagent able to image
and quantify thiols in live cells through ﬂuorescence microscopy. The
reagent was later found to be capable of quantifying thiols in as low
as 500 cells in a high throughput manner. The reagent is now named
as GUALY's reagent and will be a valuable tool in exploring the roles
of thiols in various thiol-related physiological/pathological conditions.
Another major project Dr. Guan's group is working on is to develop
approaches to treat cancer metastasis by targeting the four essential
steps (detachment, migration, invasion, and adhesion) in the metastasis
process, especially the step of detachment. Despite extensive research
efforts in the development of cancer therapeutic agents, agents for the
treatment of cancer metastasis are limited. Dr. Guan's group has
identiﬁed that glutathione disulﬁde (GSSG), when delivered properly,
is able to not only effectively inhibit cancer growth but also block
cancer metastasis through inhibition of cell detachment, migration, and
invasion. Efforts in exploring the molecular targets of these effects and
in developing GSSG as an effective therapeutic agent for the treatment
of cancer growth and metastasis are under the way.
Dr. Guan has ﬁled two patent applications, published two book
chapters, and 32 peer-reviewed articles in prestigious journals such
as Journal of Biological Chemistry, Journal of Medicinal Chem-
istry, Analytical Chemistry, Drug Metabolism and Disposition,
Chemical Research in Toxicology, Free Radical Biology and
Medicine, and Archives of Biochemistry and Biophysics. His
research has been supported continuously by National Institutes of
Health (NIH) since 1999.
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